Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report report published on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of NASDAQ:CARA opened at $0.31 on Thursday. The company’s fifty day moving average price is $0.29 and its 200-day moving average price is $0.38. The firm has a market capitalization of $16.74 million, a price-to-earnings ratio of -0.17 and a beta of 0.68. Cara Therapeutics has a one year low of $0.24 and a one year high of $1.31.

Institutional Investors Weigh In On Cara Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Cara Therapeutics during the 3rd quarter valued at about $29,000. FMR LLC grew its position in Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the last quarter. Finally, Disciplined Growth Investors Inc. MN raised its stake in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares in the last quarter. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.